Cells jostling for a spot in a germinal center face a cutthroat admissions process. Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine their response to the threat.
Antibody therapy controls HIV for months in new clinical trial miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine.
The prize recognizes breakthrough innovations by Dr. James E. Crowe Jr. and Dr. Michel C. Nussenzweig in the use of human antibodies to treat COVID-19. The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation established the prize in 2014 to honor physician-scientists 'who have moved science forward with achievements notable for innovation, creativity and potential for clinical application.'
Hope for a future without fear of COVID-19 comes down to circulating antibodies and memory B cells. Unlike circulating antibodies, which peak soon after vaccination or infection only to fade a few months later, memory B cells can stick around to prevent severe disease for decades. And they evolve over time, learning to produce successively more potent "memory antibodies" that are better at neutralizing the virus and more capable of adapting to variants.